13 results about "Normal breast" patented technology

This application example provides a breast prosthesis processing system, which includes a scanner, a data processing device, a prosthesis processing device, and a printing device. The scanner is used to scan the human body, obtain torso scan data containing images of a normal breast and the residual part after mastectomy, and send it to the data processing device. The data processing device, in response to input, marks feature points on the residual part image, mirrors them, and generates mirrored feature points. The prosthesis processing device then processes the prosthesis based on the mirrored feature points, and the printing device prints the processed prosthesis. This system aims to improve the accuracy and efficiency of breast prosthesis production, ensuring a better fit and aesthetic outcome for users. The integration of scanning, data processing, and printing technologies streamlines the entire process, providing a more personalized and precise solution for breast prosthesis manufacturing.

The invention discloses application of FIGN protein in cytoplasm as a marker in preparation of a lung adenocarcinoma and / or breast cancer diagnosis product, and belongs to the field of biomedicine. According to the application of the FIGN protein in the cytoplasm as the marker in preparation of the lung adenocarcinoma and / or breast cancer diagnosis product, the lung adenocarcinoma and / or breast cancer diagnosis product comprises a product for detecting the expression level of the FIGN protein in the cytoplasm of a sample, and the sample is collected from lung glands and / or mammary glands to be diagnosed of a subject. The sensitivity of the diagnostic predictive biomarker and the diagnostic kit in breast cancer and lung adenocarcinoma tumor tissues is 88.89% and 87.87% respectively, the sensitivity of the diagnostic predictive biomarker and the diagnostic kit in normal breast and lung tissues is 92.22% and 90.00% respectively, a new tool and a new method are provided for early diagnosis of breast cancer, lung adenocarcinoma and the like, and the diagnostic predictive biomarker and the diagnostic kit have important clinical application value.

The present invention relates to the use of FIGN protein in the cytoplasm as a marker in the preparation of a diagnostic product for lung adenocarcinoma and / or breast cancer, and is related to the biomedical field. The use of FIGN protein in the cytoplasm as a marker in the preparation of a diagnostic product for lung adenocarcinoma and / or breast cancer comprises a product for detecting the expression level of FIGN protein in the cytoplasm of a sample collected from the lung and / or breast of a subject to be diagnosed. The diagnostic predictive biomarker and diagnostic kit of the present invention have sensitivities of 88.89% and 87.87% in breast cancer and lung adenocarcinoma tumor tissues, respectively, and sensitivities of 92.22% and 90.00% in normal breast and lung tissues, respectively. These provide new tools and methods for the early diagnosis of breast cancer, lung adenocarcinoma, and other conditions, and have important clinical application value.

The embodiment of the utility model provides a flexible tee joint and a breast pump, and relates to the field of pregnant and baby products. The flexible tee joint comprises a breast cover, a suction bowl and a guide cylinder, wherein the suction bowl is arranged at the rear end of the breast cover, the suction bowl divides the breast cover into a front cavity and a rear cavity, the rear cavity drives the suction bowl to deform under the action of a negative pressure source so as to enable the front cavity to form negative pressure, the top end of the guide cylinder is communicated with the front cavity, the bottom end of the guide cylinder is used for being communicated with a milk storage container, and the breast cover, the suction bowl and the guide cylinder are integrally formed. According to the flexible tee joint, all the components are integrally formed, on the premise that normal milk sucking operation can be guaranteed, the number of the components can be reduced, and then assembling and cleaning convenience is improved.

The invention discloses application of MISP as a breast cancer diagnosis / prognosis marker and a treatment target. The in-depth study on the expression of MISP in breast cancer cells and the influence on malignant biological behaviors such as breast cancer proliferation shows that compared with normal breast epithelial cells, the MISP is highly expressed in the breast cancer cells, the expression of the MISP is highly related to poor clinical prognosis of breast cancer patients, and the proliferation of the breast cancer cells can be inhibited by reducing the expression of the MISP. A new biomarker is provided for diagnosis and prognosis of the breast cancer, a new target spot is provided for treatment of the breast cancer, and important scientific significance is achieved in the aspects of subsequent drug research and development, clinical treatment and the like.

The invention relates to a breast cancer image anomaly detection method and system based on self-supervised learning, and the method comprises the steps: based on the biophysics principle, including cell fluctuation dynamics and a tumor stress field model, generating various types of synthetic anomaly images through the simulation of a normal breast ultrasound image; the normal image and the composite image are jointly input into a feature extraction network fusing Transform and KAN for self-supervised contrast learning pre-training; after training is completed, the model is used for extracting multi-scale features of normal images to construct a normal feature memory bank; a local abnormal score is obtained by calculating the similarity distance between the to-be-detected image features and the features in the memory bank, so that accurate abnormal region recognition and positioning without manual annotation are realized; and finally, carrying out visual output on a detection result. According to the method, the problems of high dependency of labeled data, insufficient sensitivity of small lesion detection and the like are effectively solved, and the automation level of breast cancer screening and the reliability of clinical auxiliary diagnosis are remarkably improved.

This application discloses a method, apparatus, and padding material for underwear, belonging to the field of underwear padding technology. The method for manufacturing the underwear padding includes: acquiring a scanned image of a patient's breast (a normal breast); constructing a three-dimensional model of the breast based on the scanned image; determining the stress distribution of the padding material based on the three-dimensional model; determining the density distribution of the filling material for the padding according to the stress distribution; and manufacturing the padding according to the density distribution.

The invention discloses a chromene compound for resisting breast cancer as well as a preparation method, application and a preparation of the chromene compound. The chromene compound has a structural formula shown in a chemical formula 1. The application is the application of the chromene compound in preparation of anti-breast cancer drugs. The preparation comprises the chromene compound and pharmaceutically acceptable auxiliary materials. The chromene compound provided by the invention has excellent inhibitory activity on breast cancer cells and low toxicity on normal mammary epithelial cells, and provides a new choice for preparing anti-breast cancer preparations.

The present invention relates to a breast phantom, comprising: a first hydrogel that forms a simulated phantom of normal breast tissue and a second hydrogel that forms a simulated phantom of cancerous breast tissue, wherein the first hydrogel comprises cross-linked 2-hydroxyethyl acrylate and the second hydrogel comprises cross-linked methacrylate hyaluronic acid. The present invention also relates to the method of preparing said phantom and to its use.

This invention discloses a novel compound and its application in the preparation of drugs for treating triple-negative breast cancer. The invention provides a compound with a novel structure; activity studies show that this compound has excellent therapeutic effects on triple-negative breast cancer, not only inhibiting the growth and migration of triple-negative breast cancer cells but also inducing apoptosis in triple-negative breast cancer cells, while having no significant inhibitory effect on normal breast epithelial cells, and exhibiting a safety profile superior to cisplatin. This invention also provides a simple and feasible method for preparing this compound.

The invention belongs to the technical field of medicinal chemistry, and particularly discloses a platinum (IV) prodrug with ferroptosis and apoptosis induction effects as well as a preparation method and application of the platinum (IV) prodrug. According to the invention, a novel platinum (IV) compound with a ferroptosis induction effect is developed based on platinum (IV) prodrugs of salazosulfapyridine, cis-platinum and carboplatin; the platinum (IV) prodrug disclosed by the invention shows excellent anti-proliferative activity to cisplatin-sensitive and drug-resistant triple negative breast cancer cells, and compared with cisplatin, the platinum (IV) prodrug has lower activity to a normal mammary gland cell line (MCF-10A). Accumulation of reactive oxygen species (ROS) in cells can be improved by inducing DNA damage, and a mitochondrial dependent approach is activated to induce apoptosis. Meanwhile, accumulation of lipid peroxide can be remarkably promoted, xCT and GPX4 levels are reduced, and mitochondrial morphological change is induced to stimulate ferroptosis; in vivo, the cis-platinum (IV) prodrug shows strong anti-tumor activity in an MDA-MB-231 / CDDP xenograft model, and the cis-platinum (IV) prodrug has strong anti-tumor activity; the platinum (IV) prodrug has a potential application prospect in targeted therapy of triple negative breast cancer.

The invention belongs to the technical field of biosensor detection, and discloses a preparation method of an LIG-based all-solid-state ion sensor array for cell multi-ion real-time monitoring. The LIG-based all-solid-state ion sensor array is integrally formed through a laser direct writing technology, PEDOT: PSS is electrochemically deposited between an LIG substrate and an ion selective membrane to serve as a solid contact layer, formation of an interface water layer is inhibited, long-term potential drifts of Na < + >, K < + > and Ca < 2 + > electrodes are remarkably reduced, and the stability is improved by more than ten times. The constructed sensor has high sensitivity, good reversibility and low detection limit on Na < + >, K < + >, Ca < 2 + > and H < + >. The array can continuously monitor the dynamic change of the extracellular ion concentration under the stimulation of fMLP in real time, and clearly capture more severe ion response signals of breast cancer cells under chemical stimulation than normal breast cells.

The present invention belongs to the field of disease diagnosis and treatment and molecular biology technology, and specifically relates to the application of circRNA in enhancing the chemotherapy sensitivity of triple-negative breast cancer and the prognosis assessment of breast cancer patients. Through research, the present invention found that the expression of circRNA-CREIT in breast cancer tissue was significantly lower than that in the surrounding normal breast tissue, and the expression in TNBC cell lines was significantly lower than that in non-TNBC, and circRNA-CREIT overexpression was significantly correlated with a good prognosis in breast cancer patients. Overexpression of circRNA-CREIT in TNBC cell lines can significantly enhance the sensitivity of cells to the chemotherapy drug doxorubicin. Therefore, circRNA-CREIT can provide a new therapeutic target for enhancing the chemotherapy sensitivity of TNBC and provide a new predictive factor for the prognosis judgment of breast cancer patients, and therefore has good practical application value.